Mankind Pharma Management
Management criteria checks 3/4
Mankind Pharma's CEO is Sheetal Arora, appointed in Jan 2021, has a tenure of 4.83 years. total yearly compensation is ₹152.30M, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 5.39% of the company’s shares, worth ₹53.35B. The average tenure of the management team and the board of directors is 4.8 years and 8.2 years respectively.
Key information
Sheetal Arora
Chief executive officer
₹152.3m
Total compensation
| CEO salary percentage | 33.09% |
| CEO tenure | 4.8yrs |
| CEO ownership | 5.4% |
| Management average tenure | 4.8yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Mankind Pharma Limited (NSE:MANKIND) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Aug 03
We Think You Should Be Aware Of Some Concerning Factors In Mankind Pharma's (NSE:MANKIND) Earnings
Jul 23Mankind Pharma (NSE:MANKIND) Has A Pretty Healthy Balance Sheet
Jun 28The Mankind Pharma Limited (NSE:MANKIND) Full-Year Results Are Out And Analysts Have Published New Forecasts
May 24Here's Why Mankind Pharma (NSE:MANKIND) Has Caught The Eye Of Investors
May 11Mankind Pharma Limited's (NSE:MANKIND) Share Price Not Quite Adding Up
Mar 02We Ran A Stock Scan For Earnings Growth And Mankind Pharma (NSE:MANKIND) Passed With Ease
Jan 15Here's Why Mankind Pharma (NSE:MANKIND) Can Manage Its Debt Responsibly
Dec 04
Decisive Acquisition And Global Expansion Set To Revitalize Revenue Growth And Profitability
Strategic acquisitions and specialization in high-entry barrier segments are expected to enhance revenue growth and margins through synergies and R&D leverage.Mankind Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | ₹19b |
| Mar 31 2025 | ₹152m | ₹50m | ₹20b |
| Dec 31 2024 | n/a | n/a | ₹20b |
| Sep 30 2024 | n/a | n/a | ₹21b |
| Jun 30 2024 | n/a | n/a | ₹20b |
| Mar 31 2024 | ₹154m | ₹50m | ₹19b |
| Dec 31 2023 | n/a | n/a | ₹17b |
| Sep 30 2023 | n/a | n/a | ₹16b |
| Jun 30 2023 | n/a | n/a | ₹15b |
| Mar 31 2023 | ₹155m | ₹50m | ₹13b |
| Dec 31 2022 | n/a | n/a | ₹12b |
| Mar 31 2022 | ₹155m | ₹50m | ₹14b |
| Mar 31 2021 | ₹155m | n/a | ₹13b |
| Mar 31 2020 | ₹118m | n/a | ₹10b |
Compensation vs Market: Sheetal's total compensation ($USD1.72M) is above average for companies of similar size in the Indian market ($USD1.17M).
Compensation vs Earnings: Sheetal's compensation has been consistent with company performance over the past year.
CEO
Sheetal Arora (50 yo)
Mr. Sheetal Arora served as Managing Director and Director at Mankind Pharma Limited until 2021 and also serves as its Chief Executive Officer since 2021. Mr. Arora served as Director of Marketing at Manki...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Whole-Time Director & Executive Chairman | 19.6yrs | ₹259.40m | 24.41% ₹ 241.8b | |
| CEO & Whole-Time Director | 4.8yrs | ₹152.30m | 5.39% ₹ 53.3b | |
| Vice Chairman & MD | 32.9yrs | ₹287.30m | 24.99% ₹ 247.5b | |
| Whole-Time Director | no data | ₹10.70m | no data | |
| Chief Financial Officer | 9.4yrs | ₹24.23m | 0.0020% ₹ 19.5m | |
| Chief Operating Officer | 4.7yrs | ₹57.86m | 1.98% ₹ 19.6b | |
| Director of Technology | 6yrs | ₹3.91m | 0.94% ₹ 9.4b | |
| Senior President & Group Chief Information Officer | no data | ₹30.00m | 0.0025% ₹ 25.2m | |
| Chief Scientific Officer (Research Centre) | 13.9yrs | ₹46.12m | no data | |
| Director of Finance | no data | ₹86.46m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Company Secretary & Compliance officer | less than a year | no data | no data |
Experienced Management: MANKIND's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Whole-Time Director & Executive Chairman | 19.6yrs | ₹259.40m | 24.41% ₹ 241.8b | |
| CEO & Whole-Time Director | 18.2yrs | ₹152.30m | 5.39% ₹ 53.3b | |
| Vice Chairman & MD | 32.9yrs | ₹287.30m | 24.99% ₹ 247.5b | |
| Whole-Time Director | 9.2yrs | ₹10.70m | no data | |
| Non-Executive Independent Director | 3.3yrs | ₹5.10m | no data | |
| Non-Executive Independent Director | 5.8yrs | ₹6.50m | no data | |
| Non-Executive Independent Director | 7.3yrs | ₹3.80m | 0.000010% ₹ 99.0k | |
| Non-Executive Independent Director | 3.3yrs | ₹6.30m | no data |
Experienced Board: MANKIND's board of directors are considered experienced (8.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 17:27 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mankind Pharma Limited is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |